Study of androgen action in bone by analysis of androgen-receptor deficient mice

2002 ◽  
Vol 20 (6) ◽  
pp. 326-330 ◽  
Author(s):  
Takashi Sato ◽  
Hirotaka Kawano ◽  
Shigeaki Kato
Keyword(s):  
Androgen Receptor ◽  
Androgen Action ◽  
Deficient Mice

Regional Expression of Androgen Receptor Coregulators and Androgen Action in the Mouse Epididymis

2011 ◽  
Vol 32 (6) ◽  
pp. 711-717 ◽  
Author(s):  
P. Sipila ◽  
A. Krutskikh ◽  
D. A. Pujianto ◽  
M. Poutanen ◽  
I. Huhtaniemi
Keyword(s):  
Androgen Receptor ◽  
Androgen Action ◽  
Mouse Epididymis

scholarly journals Increased Estrogen Rather Than Decreased Androgen Action Is Associated with Longer Androgen Receptor CAG Repeats

2009 ◽  
Vol 94 (1) ◽  
pp. 277-284 ◽  
Author(s):  
Ilpo T. Huhtaniemi ◽  
Stephen R. Pye ◽  
Kate L. Limer ◽  
Wendy Thomson ◽  
Terence W. O'Neill ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Cag Repeats ◽  
Androgen Action

Morphology and gene expression profile of the submandibular gland of androgen-receptor-deficient mice

2015 ◽  
Vol 60 (2) ◽  
pp. 320-332 ◽  
Author(s):  
Kannika Adthapanyawanich ◽  
Tewarat Kumchantuek ◽  
Hiroki Nakata ◽  
Miyuki Yamamoto ◽  
Tomohiko Wakayama ◽  
...  
Keyword(s):  
Gene Expression ◽  
Androgen Receptor ◽  
Submandibular Gland ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Deficient Mice

scholarly journals Androgen receptor antagonists for prostate cancer therapy

2014 ◽  
Vol 21 (4) ◽  
pp. T105-T118 ◽  
Author(s):  
Christine Helsen ◽  
Thomas Van den Broeck ◽  
Arnout Voet ◽  
Stefan Prekovic ◽  
Hendrik Van Poppel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Androgen Receptor ◽  
Metastatic Prostate Cancer ◽  
Castration Resistant ◽  
Androgen Action ◽  
Conflicting Evidence ◽  
Prostate Cancer Therapy ◽  
Androgen Receptor Antagonists

Androgen deprivation is the mainstay therapy for metastatic prostate cancer (PCa). Another way of suppressing androgen receptor (AR) signaling is via AR antagonists or antiandrogens. Despite being frequently prescribed in clinical practice, there is conflicting evidence concerning the role of AR antagonists in the management of PCa. In the castration-resistant settings of PCa, docetaxel has been the only treatment option for decades. With recent evidence that castration-resistant PCa is far from AR-independent, there has been an increasing interest in developing new AR antagonists. This review gives a concise overview of the clinically available antiandrogens and the experimental AR antagonists that tackle androgen action with a different approach.

Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action

The Prostate ◽  
2004 ◽  
Vol 62 (2) ◽  
pp. 133-139 ◽  
Author(s):  
Dacheng Ding ◽  
Lihua Xu ◽  
Mani Menon ◽  
G. Prem Veer Reddy ◽  
Evelyn R. Barrack
Keyword(s):  
Androgen Receptor ◽  
Length Polymorphism ◽  
Repeat Length ◽  
Androgen Action ◽  
Human Androgen Receptor

Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations

2015 ◽  
Vol 11 (12) ◽  
pp. 3347-3354 ◽  
Author(s):  
Hongli Liu ◽  
Xiaoli An ◽  
Shuyan Li ◽  
Yuwei Wang ◽  
Jiazhong Li ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Molecular Dynamics ◽  
Androgen Receptor ◽  
Molecular Dynamics Simulations ◽  
First Generation ◽  
Interaction Mechanism ◽  
Androgen Action ◽  
Treat Prostate Cancer ◽  
Dynamics Simulations

R-Bicalutamide is a first generation antiandrogen used to treat prostate cancer, which inhibits androgen action by competitively binding to the androgen receptor (AR).

scholarly journals Development and Function of the Adult Generation of Leydig Cells in Mice with Sertoli Cell-Selective or Total Ablation of the Androgen Receptor

Endocrinology ◽  
2005 ◽  
Vol 146 (9) ◽  
pp. 4117-4126 ◽  
Author(s):  
Karel De Gendt ◽  
Nina Atanassova ◽  
Karen A. L. Tan ◽  
Luiz Renato de França ◽  
Gleydes Gambogi Parreira ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Growth Factor ◽  
Sertoli Cell ◽  
Leydig Cells ◽  
Platelet Derived Growth Factor ◽  
Testosterone Levels ◽  
Androgen Action ◽  
Serum Lh ◽  
D 12 ◽  
And Function

Abstract It is established that androgens and unidentified Sertoli cell (SC)-derived factors can influence the development of adult Leydig cells (LC) in rodents, but the mechanisms are unclear. We evaluated adult LC development and function in SC-selective androgen receptor (AR) knockout (SCARKO) and complete AR knockout (ARKO) mice. In controls, LC number increased 26-fold and LC size increased by approximately 2-fold between 12 and 140 d of age. LC number in SCARKOs was normal on d 12, but was reduced by more than 40% at later ages, although LC were larger and contained more lipid droplets and mitochondria than control LC by adulthood. ARKO LC number was reduced by up to 83% at all ages compared with controls, and LC size did not increase beyond d 12. Serum LH and testosterone levels and seminal vesicle weights were comparable in adult SCARKOs and controls, whereas LH levels were elevated 8-fold in ARKOs, although testosterone levels appeared normal. Immunohistochemistry and quantitative PCR for LC-specific markers indicated steroidogenic function per LC was probably increased in SCARKOs and reduced in ARKOs. In SCARKOs, insulin-like factor-3 and estrogen sulfotransferase (EST) mRNA expression were unchanged and increased 3-fold, respectively, compared with controls, whereas the expression of both was reduced more than 90% in ARKOs. Changes in EST expression, coupled with reduced platelet-derived growth factor-A expression, are potential causes of altered LC number and function in SCARKOs. These results show that loss of androgen action on SC has major consequences for LC development, and this could be mediated indirectly via platelet-derived growth factor-A and/or estrogens/EST.

Sign in / Sign up

Export Citation Format

Share Document